Join our email list to stay up to date on the latest Amyloidosis news.

ARC Executive Director of Research Kristen Hsu presented an overview of the different approaches to treating ATTR amyloidosis, as well as the most current updates for the clinical trial landscape, with a focus on ATTR trials.

Original Presentation Date:
July 31, 2025.

Download the Slides

 

0:00 — Welcome

3:11 — Introduction

6:44 — Overview of Approaches to ATTR Amyloidosis Treatments

10:37 — Investigative Approaches to ATTR Amyloidosis Treatments

13:36 — ATTR Clinical Trials 2025 Overview & Updates

17:30 — ATTR Clinical Trials Currently Recruiting

18:20 — ACT-EARLY (acoramidis; TTR stabilizer)

25:53 — TRITON-CM (nucresiran; gene silencer)

30:12 — MAGNITUDE (nex-z; CRISPR gene editing)

33:37 — MAGNITUDE-2 (nex-z; CRISPR gene editing)

35:39 — Upcoming Milestones for Novel ATTR Therapies

36:52 — CARDIO-TTRansform (eplontersen; gene silencer)

38:08 — Coramitug (NNC6019-0001; anti-amyloid fibril depleter)

39:36 — DepleTTR-CM (ALXN2220; anti-amyloid fibril depleter)

41:08 — How long does FDA approval take after Phase 3 trials?

45:20 — Other Recruiting and Planned Clinical Studies

47:55 — REVEAL (I-124 Evuzamitide; diagnostic radiotracer)

48:48 — CArdiag ([18F]Florbetaben; diagnostic radiotracer)

49:21 — How to Find Clinical Trials

52:27 — Q&A Session

52:46 — Why are there different ATTR-PN (polyneuropathy) and ATTR-CM (cardiomyopathy) trials?

56:16 — Why are there no anti-fibril studies for ATTR-PN?

57:50 — Why are the inclusion criteria for the MAGNITUDE study so high?

59:55 — Conclusion

 

Contact ARC:

Call +1 (617) 467-5170

Email ARC at support@arci.org

 

*

*

*









*